Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Parkinson's HelpLine

 

Learn More

Educational Materials

  publications

Do you want to know more about Parkinson's? PDF's materials provide information about symptoms, medications, resources & more.

Order Free Materials Today


Science News

Impax Gets Approval For Parkinson's Drug - Generic Version of Sinemet CR

Impax Laboratories Inc. said Monday it got its sixth FDA drug approval this year for generic versions of Sinemet CR tablets, which is used to treat Parkinson's disease.

Sinemet is currently sold in the United States by Bristol-Myers Squibb. Hayward-based Impax will call its version of the drug Carbidopa/Levodopa Extended Release Tablets. The company said U.S. prescription sales of Sinemet CR and the one currently marketed generic equivalent were $126 million in the 12 months ended Feb. 29.

Parkinson's Disease is a progressive degenerative disease of the nerves.

Impax currently has 16 applications pending at the FDA, including five tentatively approved, which the company says address approximately $5.3 billion in U.S. market sales for the 12 months ended Feb. 29.

Source Date: May 17 2004
Source Publication: San Francisco Business Times, CA
View source URL